BioCentury | Feb 13, 2018
Distillery Therapeutics

Inflammation; infectious disease

...2018 doi:10.1038/s41467-018-02896-8 CONTACT: Karlheinz Peter, Baker Heart and Diabetes Institute, Melbourne, Australia email: karlheinz.peter@baker.edu.au Claire Quang Baker IDI...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

...J. Clin. Invest. ; published online May 15, 2017 doi:10.1172/JCI92450 CONTACT: Andrew J. Murphy, Baker IDI...
...andrew.murphy@bakeridi.edu.au CONTACT: Prabhakara R. Nagareddy, University of Alabama at Birmingham, Birmingham, Ala. email: pnreddy@uab.edu Hongjiang Li Baker IDI...
BioCentury | Mar 23, 2017
Financial News

Advicenne completes venture financing

...Pharma S.A. (Nimes, France) raised €16 million ($17.2 million) in a financing round led by IDI...
BioCentury | Feb 22, 2017
Distillery Therapeutics

Cardiovascular

...CONTACT: Rebecca H. Ritchie, Baker IDI Heart and Diabetes Institute, Melbourne, Australia email: rebecca.ritchie@bakeridi.edu.au Hongjiang Li Baker IDI...
BioCentury | Dec 6, 2016
Distillery Therapeutics

Endocrine / Metabolic

...doi:10.1016/j.cmet.2016.10.002 CONTACT: Bhagirath Chaurasia, Baker IDI Heart and Diabetes Institute, Melbourne, Australia email: bhagirath.chaurasia@health.utah.edu Hongjiang Li Baker IDI...
BioCentury | Jan 4, 2016
Company News

Clinigen Group, Sunesis sales and marketing update

Clinigen's Idis Managed Access division partnered with Sunesis to manage a compassionate use program for Qinprezo vosaroxin to treat relapsed or refractory acute myelogenous leukemia (AML). The program is available to patients in the U.S....
BioCentury | Nov 23, 2015
Company News

Clinigen Group, United Therapeutics sales and marketing update

The U.K.’s NICE issued draft guidance recommending against Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma in combination with GM-CSF, IL-2 and isotretinoin in patients ages 12 months to 17 years -- its approved...
BioCentury | Nov 16, 2015
Regulation

Scaling compassion

Nearly two years after a viral media campaign saved seven-year-old Josh Hardy's life and put demands for access to unapproved medicines on front pages, drug companies, FDA, academic bioethicists, and patient advocates are beginning to...
BioCentury | Oct 19, 2015
Company News

Link Healthcare, Clinigen Group deal

Clinigen will acquire Link for L22.3 million ($34.2 million) in cash, 3.1 million shares and up to L55.5 million ($84.5 million) in cash milestones. The shares are valued at L23.3 million ($35.8 million) based on...
BioCentury | Jun 8, 2015
Company News

IDIS Ltd., Clinigen Group deal

Clinigen acquired fellow drug management and supply company IDIS for L135 million ($205.9 million) in a stock deal. Clinigen issued 27 million new shares at 500p. The price is a 24% discount to Clinigen’s close...
Items per page:
1 - 10 of 55
BioCentury | Feb 13, 2018
Distillery Therapeutics

Inflammation; infectious disease

...2018 doi:10.1038/s41467-018-02896-8 CONTACT: Karlheinz Peter, Baker Heart and Diabetes Institute, Melbourne, Australia email: karlheinz.peter@baker.edu.au Claire Quang Baker IDI...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

...J. Clin. Invest. ; published online May 15, 2017 doi:10.1172/JCI92450 CONTACT: Andrew J. Murphy, Baker IDI...
...andrew.murphy@bakeridi.edu.au CONTACT: Prabhakara R. Nagareddy, University of Alabama at Birmingham, Birmingham, Ala. email: pnreddy@uab.edu Hongjiang Li Baker IDI...
BioCentury | Mar 23, 2017
Financial News

Advicenne completes venture financing

...Pharma S.A. (Nimes, France) raised €16 million ($17.2 million) in a financing round led by IDI...
BioCentury | Feb 22, 2017
Distillery Therapeutics

Cardiovascular

...CONTACT: Rebecca H. Ritchie, Baker IDI Heart and Diabetes Institute, Melbourne, Australia email: rebecca.ritchie@bakeridi.edu.au Hongjiang Li Baker IDI...
BioCentury | Dec 6, 2016
Distillery Therapeutics

Endocrine / Metabolic

...doi:10.1016/j.cmet.2016.10.002 CONTACT: Bhagirath Chaurasia, Baker IDI Heart and Diabetes Institute, Melbourne, Australia email: bhagirath.chaurasia@health.utah.edu Hongjiang Li Baker IDI...
BioCentury | Jan 4, 2016
Company News

Clinigen Group, Sunesis sales and marketing update

Clinigen's Idis Managed Access division partnered with Sunesis to manage a compassionate use program for Qinprezo vosaroxin to treat relapsed or refractory acute myelogenous leukemia (AML). The program is available to patients in the U.S....
BioCentury | Nov 23, 2015
Company News

Clinigen Group, United Therapeutics sales and marketing update

The U.K.’s NICE issued draft guidance recommending against Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma in combination with GM-CSF, IL-2 and isotretinoin in patients ages 12 months to 17 years -- its approved...
BioCentury | Nov 16, 2015
Regulation

Scaling compassion

Nearly two years after a viral media campaign saved seven-year-old Josh Hardy's life and put demands for access to unapproved medicines on front pages, drug companies, FDA, academic bioethicists, and patient advocates are beginning to...
BioCentury | Oct 19, 2015
Company News

Link Healthcare, Clinigen Group deal

Clinigen will acquire Link for L22.3 million ($34.2 million) in cash, 3.1 million shares and up to L55.5 million ($84.5 million) in cash milestones. The shares are valued at L23.3 million ($35.8 million) based on...
BioCentury | Jun 8, 2015
Company News

IDIS Ltd., Clinigen Group deal

Clinigen acquired fellow drug management and supply company IDIS for L135 million ($205.9 million) in a stock deal. Clinigen issued 27 million new shares at 500p. The price is a 24% discount to Clinigen’s close...
Items per page:
1 - 10 of 55